Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Frank McCormick, PhD, FRS

    TitleDirector, Comprehensive Cancer Center and Cancer Research Institute
    SchoolUCSF School of Medicine
    DepartmentHDF Comprehensive Cancer Center
    Address1450 3rd Street
    San Francisco CA 94158
    Phone415-502-1710

       Overview 
       Overview
      Frank McCormick, PhD, FRS, is Director of the UCSF Helen Diller Family Comprehensive Cancer Center. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms and held positions with Cetus Corporation (Director of Molecular Biology, 1981-1990; Vice President of Research, 1990-1991) and Chiron Corporation, where he was Vice President of Research from 1991 to 1992. In 1992 he founded Onyx Pharmaceuticals, a company dedicated to developing new cancer therapies, and served as its Chief Scientific Officer until 1996. At Onyx Pharmaceuticals, he initiated and led drug discovery efforts that led to the approval of Sorafenib in 2005 for treatment of renal cell cancer, and for liver cancer in 2007, and the approval of ONYX-015 in 2006 in China for treatment of nasopharyngeal cancer. Sorafenib is being tested in multiple indications worldwide. In addition, Dr. McCormick’s group led to the identification of a CDK4 kinase inhibitor. Dr. McCormick's current research interests center on the fundamental differences between normal and cancer cells that can allow the discovery of novel therapeutic strategies.

      In addition to his position as director of the UCSF HDFCCC, Dr. McCormick holds the David A. Wood Chair of Tumor Biology and Cancer Research in UCSF's Department of Microbiology and Immunology. Dr. McCormick is the author of over 285 scientific publications and holds 20 issued patents. He also served as President, 2012-2013 for the American Association for Cancer Research (AACR). More recently, he has taken a leadership role at the Frederick National Lab for Cancer Research, overseeing an NCI supported national effort to develop therapies against Ras-driven cancers. These cancers include most pancreatic cancers, and many colorectal and lung cancers, and are amongst the most difficult cancers to treat.


       ORNG Applications 
       Websites
       In The News
       Awarded Grants
       More Info

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Yuan TL, McCormick F. Killing Tumors by Keeping Ras and PI3' Kinase Apart. Cancer Cell. 2013 Nov 11; 24(5):562-3.
        View in: PubMed
      2. Nan X, Collisson EA, Lewis S, Huang J, Tamgüney TM, Liphardt JT, McCormick F, Gray JW, Chu S. Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. Proc Natl Acad Sci U S A. 2013 Nov 12; 110(46):18519-24.
        View in: PubMed
      3. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padró M, Daemen A, Hu M, Chan DA, Ethier SP, van 't Veer LJ, Polyak K, McCormick F, Gray JW. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013 Oct 14; 24(4):450-65.
        View in: PubMed
      4. Lyons J, Bastian BC, McCormick F. MC1R and cAMP signaling inhibit cdc25B activity and delay cell cycle progression in melanoma cells. Proc Natl Acad Sci U S A. 2013 Aug 20; 110(34):13845-50.
        View in: PubMed
      5. Holderfield M, Merritt H, Chan J, Wallroth M, Tandeske L, Zhai H, Tellew J, Hardy S, Hekmat-Nejad M, Stuart DD, McCormick F, Nagel TE. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell. 2013 May 13; 23(5):594-602.
        View in: PubMed
      6. McCormick F, Cvetanovich GL, Kim JM, Harris JD, Gupta AK, Abrams GD, Romeo AA, Provencher MT. An assessment of the quality of rotator cuff randomized controlled trials: utilizing the Jadad score and CONSORT criteria. J Shoulder Elbow Surg. 2013 Sep; 22(9):1180-5.
        View in: PubMed
      7. Young A, Lou D, McCormick F. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov. 2013 Jan; 3(1):112-23.
        View in: PubMed
      8. Stowe IB, Mercado EL, Stowe TR, Bell EL, Oses-Prieto JA, Hernández H, Burlingame AL, McCormick F. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. Genes Dev. 2012 Jul 1; 26(13):1421-6.
        View in: PubMed
      9. Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, Koso T, Matsumoto Y, Wada-Hiraike O, Kawana K, Kuramoto H, McCormick F, Aburatani H, Yano T, Kozuma S, Taketani Y. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS One. 2012; 7(5):e37431.
        View in: PubMed
      10. McCormick F. Cancer therapy based on oncogene addiction. J Surg Oncol. 2011 May 1; 103(6):464-7.
        View in: PubMed
      11. Rauen KA, Banerjee A, Bishop WR, Lauchle JO, McCormick F, McMahon M, Melese T, Munster PN, Nadaf S, Packer RJ, Sebolt-Leopold J, Viskochil DH. Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet. 2011 May 15; 157C(2):136-46.
        View in: PubMed
      12. Gysin S, Salt M, Young A, McCormick F. Therapeutic strategies for targeting ras proteins. Genes Cancer. 2011 Mar; 2(3):359-72.
        View in: PubMed
      13. McCormick F. Mutant onco-proteins as drug targets: successes, failures, and future prospects. Curr Opin Genet Dev. 2011 Feb; 21(1):29-33.
        View in: PubMed
      14. Lee SH, McCormick F, Saya H. Mad2 inhibits the mitotic kinesin MKlp2. J Cell Biol. 2010 Dec 13; 191(6):1069-77.
        View in: PubMed
      15. Lyle C, McCormick F. Integrin alphavbeta5 is a primary receptor for adenovirus in CAR-negative cells. Virol J. 2010; 7:148.
        View in: PubMed
      16. Ishida S, McCormick F, Smith-McCune K, Hanahan D. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell. 2010 Jun 15; 17(6):574-83.
        View in: PubMed
      17. Harris TJ, McCormick F. The molecular pathology of cancer. Nat Rev Clin Oncol. 2010 May; 7(5):251-65.
        View in: PubMed
      18. Phan VT, Ding VW, Li F, Chalkley RJ, Burlingame A, McCormick F. The RasGAP proteins Ira2 and neurofibromin are negatively regulated by Gpb1 in yeast and ETEA in humans. Mol Cell Biol. 2010 May; 30(9):2264-79.
        View in: PubMed
      19. Kissil JL, Blakeley JO, Ferner RE, Huson SM, Kalamarides M, Mautner VF, McCormick F, Morrison H, Packer R, Ramesh V, Ratner N, Rauen KA, Stevenson DA, Hunter-Schaedle K, North K. What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers. Am J Med Genet A. 2010 Feb; 152A(2):269-83.
        View in: PubMed
      20. McCormick F. How blocking Raf activates the MAPK pathway. Pigment Cell Melanoma Res. 2010 Apr; 23(2):187-9.
        View in: PubMed
      21. Murayama-Hosokawa S, Oda K, Nakagawa S, Ishikawa S, Yamamoto S, Shoji K, Ikeda Y, Uehara Y, Fukayama M, McCormick F, Yano T, Taketani Y, Aburatani H. Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway. Oncogene. 2010 Apr 1; 29(13):1897-908.
        View in: PubMed
      22. Rauen KA, Schoyer L, McCormick F, Lin AE, Allanson JE, Stevenson DA, Gripp KW, Neri G, Carey JC, Legius E, Tartaglia M, Schubbert S, Roberts AE, Gelb BD, Shannon K, Gutmann DH, McMahon M, Guerra C, Fagin JA, Yu B, Aoki Y, Neel BG, Balmain A, Drake RR, Nolan GP, Zenker M, Bollag G, Sebolt-Leopold J, Gibbs JB, Silva AJ, Patton EE, Viskochil DH, Kieran MW, Korf BR, Hagerman RJ, Packer RJ, Melese T. Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A. 2010 Jan; 152A(1):4-24.
        View in: PubMed
      23. Fan QW, Cheng C, Knight ZA, Haas-Kogan D, Stokoe D, James CD, McCormick F, Shokat KM, Weiss WA. EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci Signal. 2009; 2(55):ra4.
        View in: PubMed
      24. Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, Spellman PT, Shokat KM, Wyrobek AJ, Bissell MJ, McCormick F, Kuo WL, Mills GB, Gray JW, Korn WM. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 2009 Jan 15; 69(2):565-72.
        View in: PubMed
      25. Young A, Lyons J, Miller AL, Phan VT, Alarcón IR, McCormick F. Ras signaling and therapies. Adv Cancer Res. 2009; 102:1-17.
        View in: PubMed
      26. Lee SH, Sterling H, Burlingame A, McCormick F. Tpr directly binds to Mad1 and Mad2 and is important for the Mad1-Mad2-mediated mitotic spindle checkpoint. Genes Dev. 2008 Nov 1; 22(21):2926-31.
        View in: PubMed
      27. Oda K, Okada J, Timmerman L, Rodriguez-Viciana P, Stokoe D, Shoji K, Taketani Y, Kuramoto H, Knight ZA, Shokat KM, McCormick F. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res. 2008 Oct 1; 68(19):8127-36.
        View in: PubMed
      28. Weisenberger DJ, Trinh BN, Campan M, Sharma S, Long TI, Ananthnarayan S, Liang G, Esteva FJ, Hortobagyi GN, McCormick F, Jones PA, Laird PW. DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight. Nucleic Acids Res. 2008 Aug; 36(14):4689-98.
        View in: PubMed
      29. Oehler VG, Qin J, Ramakrishnan R, Facer G, Ananthnarayan S, Cummings C, Deininger M, Shah N, McCormick F, Willis S, Daridon A, Unger M, Radich JP. Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR. Leukemia. 2009 Feb; 23(2):396-9.
        View in: PubMed
      30. Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Oncogene. 2008 Sep 11; 27(40):5303-14.
        View in: PubMed
      31. Rauen KA, Hefner E, Carrillo K, Taylor J, Messier L, Aoki Y, Gripp KW, Matsubara Y, Proud VK, Hammond P, Allanson JE, Delrue MA, Axelrad ME, Lin AE, Doyle DA, Kerr B, Carey JC, McCormick F, Silva AJ, Kieran MW, Hinek A, Nguyen TT, Schoyer L. Molecular aspects, clinical aspects and possible treatment modalities for Costello syndrome: Proceedings from the 1st International Costello Syndrome Research Symposium 2007. Am J Med Genet A. 2008 May 1; 146A(9):1205-17.
        View in: PubMed
      32. Yeang CH, McCormick F, Levine A. Combinatorial patterns of somatic gene mutations in cancer. FASEB J. 2008 Aug; 22(8):2605-22.
        View in: PubMed
      33. Kitagawa M, Lee SH, McCormick F. Skp2 suppresses p53-dependent apoptosis by inhibiting p300. Mol Cell. 2008 Feb 1; 29(2):217-31.
        View in: PubMed
      34. Estep AL, Palmer C, McCormick F, Rauen KA. Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS One. 2007; 2(12):e1279.
        View in: PubMed
      35. Senawong T, Phuchareon J, Ohara O, McCormick F, Rauen KA, Tetsu O. Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options. Hum Mol Genet. 2008 Feb 1; 17(3):419-30.
        View in: PubMed
      36. Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Kondo S, McCormick F, Xu J, Kondo Y, Bekele BN, Colman H, Lang FF, Fueyo J. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst. 2007 Sep 19; 99(18):1410-4.
        View in: PubMed
      37. McCormick F. Success and failure on the ras pathway. Cancer Biol Ther. 2007 Oct; 6(10):1654-9.
        View in: PubMed
      38. Iacovides DC, O'Shea CC, Oses-Prieto J, Burlingame A, McCormick F. Critical role for arginine methylation in adenovirus-infected cells. J Virol. 2007 Dec; 81(23):13209-17.
        View in: PubMed
      39. Ding VW, Lin LP, Chiang AL, McCormick F. Activation of p53 by Dishevelled independent of Wnt or planar polarity pathways. J Mol Med (Berl). 2007 Nov; 85(11):1281-9.
        View in: PubMed
      40. Okabe H, Lee SH, Phuchareon J, Albertson DG, McCormick F, Tetsu O. A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS One. 2006; 1:e128.
        View in: PubMed
      41. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006 Dec; 10(6):515-27.
        View in: PubMed
      42. Lee SH, McCormick F. p97/DAP5 is a ribosome-associated factor that facilitates protein synthesis and cell proliferation by modulating the synthesis of cell cycle proteins. EMBO J. 2006 Sep 6; 25(17):4008-19.
        View in: PubMed
      43. Jiang H, McCormick F, Lang FF, Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses as antiglioma agents. Expert Rev Anticancer Ther. 2006 May; 6(5):697-708.
        View in: PubMed
      44. Rodriguez-Viciana P, Oses-Prieto J, Burlingame A, Fried M, McCormick F. A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. Mol Cell. 2006 Apr 21; 22(2):217-30.
        View in: PubMed
      45. Rodriguez-Viciana P, McCormick F. Ras ubiquitination: coupling spatial sorting and signal transmission. Cancer Cell. 2006 Apr; 9(4):243-4.
        View in: PubMed
      46. Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science. 2006 Mar 3; 311(5765):1287-90.
        View in: PubMed
      47. Gomez-Manzano C, Alonso MM, Yung WK, McCormick F, Curiel DT, Lang FF, Jiang H, Bekele BN, Zhou X, Alemany R, Fueyo J. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res. 2006 Jan 15; 12(2):556-62.
        View in: PubMed
      48. You L, Kim J, He B, Xu Z, McCormick F, Jablons DM. Wnt-1 signal as a potential cancer therapeutic target. Drug News Perspect. 2006 Jan-Feb; 19(1):27-31.
        View in: PubMed
      49. Rodriguez-Viciana P, McCormick F. Characterization of interactions between ras family GTPases and their effectors. Methods Enzymol. 2006; 407:187-94.
        View in: PubMed
      50. Oda K, Stokoe D, Taketani Y, McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 2005 Dec 1; 65(23):10669-73.
        View in: PubMed
      51. McCormick F. Future prospects for oncolytic therapy. Oncogene. 2005 Nov 21; 24(52):7817-9.
        View in: PubMed
      52. Mazieres J, You L, He B, Xu Z, Lee AY, Mikami I, McCormick F, Jablons DM. Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis. Oncogene. 2005 Aug 11; 24(34):5396-400.
        View in: PubMed
      53. Reid TR, Freeman S, Post L, McCormick F, Sze DY. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther. 2005 Aug; 12(8):673-81.
        View in: PubMed
      54. Macrae M, Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J, Chen C, Gray JW, McCormick F. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell. 2005 Aug; 8(2):111-8.
        View in: PubMed
      55. O'Shea CC, Choi S, McCormick F, Stokoe D. Adenovirus overrides cellular checkpoints for protein translation. Cell Cycle. 2005 Jul; 4(7):883-8.
        View in: PubMed
      56. O'Shea CC, Soria C, Bagus B, McCormick F. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell. 2005 Jul; 8(1):61-74.
        View in: PubMed
      57. Klein S, McCormick F, Levitzki A. Killing time for cancer cells. Nat Rev Cancer. 2005 Jul; 5(7):573-80.
        View in: PubMed
      58. He B, Reguart N, You L, Mazieres J, Xu Z, Lee AY, Mikami I, McCormick F, Jablons DM. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene. 2005 Apr 21; 24(18):3054-8.
        View in: PubMed
      59. O'Shea C, Klupsch K, Choi S, Bagus B, Soria C, Shen J, McCormick F, Stokoe D. Adenoviral proteins mimic nutrient/growth signals to activate the mTOR pathway for viral replication. EMBO J. 2005 Mar 23; 24(6):1211-21.
        View in: PubMed
      60. Rodriguez-Viciana P, McCormick F. RalGDS comes of age. Cancer Cell. 2005 Mar; 7(3):205-6.
        View in: PubMed
      61. He B, Lee AY, Dadfarmay S, You L, Xu Z, Reguart N, Mazieres J, Mikami I, McCormick F, Jablons DM. Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells. Cancer Res. 2005 Feb 1; 65(3):743-8.
        View in: PubMed
      62. Rodriguez-Viciana P, Tetsu O, Oda K, Okada J, Rauen K, McCormick F. Cancer targets in the Ras pathway. Cold Spring Harb Symp Quant Biol. 2005; 70:461-7.
        View in: PubMed
      63. Lee SH, McCormick F. Downregulation of Skp2 and p27/Kip1 synergistically induces apoptosis in T98G glioblastoma cells. J Mol Med (Berl). 2005 Apr; 83(4):296-307.
        View in: PubMed
      64. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Kunich J, Shen Y, Habets G, Ginzinger D, McCormick F. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 2004 Dec; 6(6):611-23.
        View in: PubMed
      65. Brandts CH, Bilanges B, Hare G, McCormick F, Stokoe D. Phosphorylation-independent stabilization of p27kip1 by the phosphoinositide 3-kinase pathway in glioblastoma cells. J Biol Chem. 2005 Jan 21; 280(3):2012-9.
        View in: PubMed
      66. Sheng T, Li C, Zhang X, Chi S, He N, Chen K, McCormick F, Gatalica Z, Xie J. Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer. 2004 Oct 13; 3:29.
        View in: PubMed
      67. Reguart N, He B, Xu Z, You L, Lee AY, Mazieres J, Mikami I, Batra S, Rosell R, McCormick F, Jablons DM. Cloning and characterization of the promoter of human Wnt inhibitory factor-1. Biochem Biophys Res Commun. 2004 Oct 8; 323(1):229-34.
        View in: PubMed
      68. Moule MG, Collins CH, McCormick F, Fried M. Role for PP2A in ARF signaling to p53. Proc Natl Acad Sci U S A. 2004 Sep 28; 101(39):14063-6.
        View in: PubMed
      69. Lee AY, He B, You L, Dadfarmay S, Xu Z, Mazieres J, Mikami I, McCormick F, Jablons DM. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene. 2004 Aug 26; 23(39):6672-6.
        View in: PubMed
      70. You L, He B, Xu Z, Uematsu K, Mazieres J, Mikami I, Reguart N, Moody TW, Kitajewski J, McCormick F, Jablons DM. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene. 2004 Aug 12; 23(36):6170-4.
        View in: PubMed
      71. You L, He B, Xu Z, Uematsu K, Mazieres J, Fujii N, Mikami I, Reguart N, McIntosh JK, Kashani-Sabet M, McCormick F, Jablons DM. An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res. 2004 Aug 1; 64(15):5385-9.
        View in: PubMed
      72. Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, Reguart N, Rosell R, McCormick F, Jablons DM. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res. 2004 Jul 15; 64(14):4717-20.
        View in: PubMed
      73. Rodriguez-Viciana P, Sabatier C, McCormick F. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol. 2004 Jun; 24(11):4943-54.
        View in: PubMed
      74. You L, He B, Uematsu K, Xu Z, Mazieres J, Lee A, McCormick F, Jablons DM. Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells. Cancer Res. 2004 May 15; 64(10):3474-8.
        View in: PubMed
      75. McCormick F. Cancer: survival pathways meet their end. Nature. 2004 Mar 18; 428(6980):267-9.
        View in: PubMed
      76. You L, He B, Xu Z, McCormick F, Jablons DM. Future directions: oncolytic viruses. Clin Lung Cancer. 2004 Jan; 5(4):226-30.
        View in: PubMed
      77. He B, You L, Uematsu K, Xu Z, Lee AY, Matsangou M, McCormick F, Jablons DM. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia. 2004 Jan-Feb; 6(1):7-14.
        View in: PubMed
      78. Timmerman LA, Grego-Bessa J, Raya A, Bertrán E, Pérez-Pomares JM, Díez J, Aranda S, Palomo S, McCormick F, Izpisúa-Belmonte JC, de la Pompa JL. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 2004 Jan 1; 18(1):99-115.
        View in: PubMed
      79. He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F, Jablons DM. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A. 2003 Nov 25; 100(24):14133-8.
        View in: PubMed
      80. Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene. 2003 Oct 16; 22(46):7218-21.
        View in: PubMed
      81. Uematsu K, Kanazawa S, You L, He B, Xu Z, Li K, Peterlin BM, McCormick F, Jablons DM. Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res. 2003 Aug 1; 63(15):4547-51.
        View in: PubMed
      82. Albertson DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumors. Nat Genet. 2003 Aug; 34(4):369-76.
        View in: PubMed
      83. McCormick F. Cancer-specific viruses and the development of ONYX-015. Cancer Biol Ther. 2003 Jul-Aug; 2(4 Suppl 1):S157-60.
        View in: PubMed
      84. Anders M, Christian C, McMahon M, McCormick F, Korn WM. Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res. 2003 May 1; 63(9):2088-95.
        View in: PubMed
      85. Jensen RH, Tiirikainen M, You L, Ginzinger D, He B, Uematsu K, Xu Z, Treseler P, McCormick F, Jablons DM. Genomic alterations in human mesothelioma including high resolution mapping of common regions of DNA loss in chromosome arm 6q. Anticancer Res. 2003 May-Jun; 23(3B):2281-9.
        View in: PubMed
      86. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell. 2003 Mar; 3(3):233-45.
        View in: PubMed
      87. He B, You L, Uematsu K, Matsangou M, Xu Z, He M, McCormick F, Jablons DM. Cloning and characterization of a functional promoter of the human SOCS-3 gene. Biochem Biophys Res Commun. 2003 Feb 7; 301(2):386-91.
        View in: PubMed
      88. Gump J, Stokoe D, McCormick F. Phosphorylation of p16INK4A correlates with Cdk4 association. J Biol Chem. 2003 Feb 28; 278(9):6619-22.
        View in: PubMed
      89. Yang CT, You L, Lin YC, Lin CL, Mccormick F, Jablons DM. A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells. Anticancer Res. 2003 Jan-Feb; 23(1A):33-8.
        View in: PubMed
      90. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2002 Aug; 2(2):103-12.
        View in: PubMed
      91. Xia C, Xu Z, Yuan X, Uematsu K, You L, Li K, Li L, McCormick F, Jablons DM. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther. 2002 Jul; 1(9):687-94.
        View in: PubMed
      92. Rauen KA, Sudilovsky D, Le JL, Chew KL, Hann B, Weinberg V, Schmitt LD, McCormick F. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res. 2002 Jul 1; 62(13):3812-8.
        View in: PubMed
      93. Sabbatini P, McCormick F. MDMX inhibits the p300/CBP-mediated acetylation of p53. DNA Cell Biol. 2002 Jul; 21(7):519-25.
        View in: PubMed
      94. Johnson L, Shen A, Boyle L, Kunich J, Pandey K, Lemmon M, Hermiston T, Giedlin M, McCormick F, Fattaey A. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell. 2002 May; 1(4):325-37.
        View in: PubMed
      95. Biederer C, Ries S, Brandts CH, McCormick F. Replication-selective viruses for cancer therapy. J Mol Med (Berl). 2002 Mar; 80(3):163-75.
        View in: PubMed
      96. McCormick F. Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer. 2001 Nov; 1(2):130-41.
        View in: PubMed
      97. Wakita K, McCormick F, Tetsu O. Method for screening ecdysone-inducible stable cell lines. Biotechniques. 2001 Aug; 31(2):414-8.
        View in: PubMed
      98. Xie J, Aszterbaum M, Zhang X, Bonifas JM, Zachary C, Epstein E, McCormick F. A role of PDGFRalpha in basal cell carcinoma proliferation. Proc Natl Acad Sci U S A. 2001 Jul 31; 98(16):9255-9.
        View in: PubMed
      99. Chen RH, McCormick F. Selective targeting to the hyperactive beta-catenin/T-cell factor pathway in colon cancer cells. Cancer Res. 2001 Jun 1; 61(11):4445-9.
        View in: PubMed
      100. Yount GL, Afshar G, Ries S, Korn M, Shalev N, Basila D, McCormick F, Haas-Kogan DA. Transcriptional activation of TRADD mediates p53-independent radiation-induced apoptosis of glioma cells. Oncogene. 2001 May 17; 20(22):2826-35.
        View in: PubMed
      101. Park JW, McCormick F. ErbB receptors and Ras: upstream, downstream? Cancer J. 2001 May-Jun; 7(3):178-80.
        View in: PubMed
      102. Wakita K, Tetsu O, McCormick F. A mammalian two-hybrid system for adenomatous polyposis coli-mutated colon cancer therapeutics. Cancer Res. 2001 Feb 1; 61(3):854-8.
        View in: PubMed
      103. McCormick F. ONYX-015 selectivity and the p14ARF pathway. Oncogene. 2000 Dec 27; 19(56):6670-2.
        View in: PubMed
      104. McCormick F. Small-molecule inhibitors of cell signaling. Curr Opin Biotechnol. 2000 Dec; 11(6):593-7.
        View in: PubMed
      105. McCormick F. Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015. Semin Cancer Biol. 2000 Dec; 10(6):453-9.
        View in: PubMed
      106. Ding VW, Chen RH, McCormick F. Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling. J Biol Chem. 2000 Oct 20; 275(42):32475-81.
        View in: PubMed
      107. Ries S, Biederer C, Woods D, Shifman O, Shirasawa S, Sasazuki T, McMahon M, Oren M, McCormick F. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell. 2000 Oct 13; 103(2):321-30.
        View in: PubMed
      108. Ries SJ, Brandts CH, Chung AS, Biederer CH, Hann BC, Lipner EM, McCormick F, Korn WM. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med. 2000 Oct; 6(10):1128-33.
        View in: PubMed
      109. Biederer CH, Ries SJ, Moser M, Florio M, Israel MA, McCormick F, Buettner R. The basic helix-loop-helix transcription factors myogenin and Id2 mediate specific induction of caveolin-3 gene expression during embryonic development. J Biol Chem. 2000 Aug 25; 275(34):26245-51.
        View in: PubMed
      110. Chen RH, Ding WV, McCormick F. Wnt signaling to beta-catenin involves two interactive components. Glycogen synthase kinase-3beta inhibition and activation of protein kinase C. J Biol Chem. 2000 Jun 9; 275(23):17894-9.
        View in: PubMed
      111. Yang CT, You L, Yeh CC, Chang JW, Zhang F, McCormick F, Jablons DM. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst. 2000 Apr 19; 92(8):636-41.
        View in: PubMed
      112. Tominaga T, Sahai E, Chardin P, McCormick F, Courtneidge SA, Alberts AS. Diaphanous-related formins bridge Rho GTPase and Src tyrosine kinase signaling. Mol Cell. 2000 Jan; 5(1):13-25.
        View in: PubMed
      113. McCormick F. Signalling networks that cause cancer. Trends Cell Biol. 1999 Dec; 9(12):M53-6.
        View in: PubMed
      114. Sabbatini P, McCormick F. Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis. J Biol Chem. 1999 Aug 20; 274(34):24263-9.
        View in: PubMed
      115. McCormick F. Cancer therapy based on p53. Cancer J Sci Am. 1999 May-Jun; 5(3):139-44.
        View in: PubMed
      116. Chardin P, McCormick F. Brefeldin A: the advantage of being uncompetitive. Cell. 1999 Apr 16; 97(2):153-5.
        View in: PubMed
      117. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999 Apr 1; 398(6726):422-6.
        View in: PubMed
      118. McCormick F. Going for the GAP. Curr Biol. 1998 Sep 24; 8(19):R673-4.
        View in: PubMed
      119. Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, Painter GF, Holmes AB, McCormick F, Hawkins PT. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science. 1997 Jul 25; 277(5325):567-70.
        View in: PubMed
      120. McCormick F. The superfamily of Ras-related GTPases. Jpn J Cancer Res. 1997 Jul; 88(7):inside front cover.
        View in: PubMed
      121. Shannon KM, O'Connell P, Martin GA, Paderanga D, Olson K, Dinndorf P, McCormick F. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med. 1994 Mar 3; 330(9):597-601.
        View in: PubMed
      122. Goretzki PE, Lyons J, Stacy-Phipps S, Rosenau W, Demeure M, Clark OH, McCormick F, Röher HD, Bourne HR. Mutational activation of RAS and GSP oncogenes in differentiated thyroid cancer and their biological implications. World J Surg. 1992 Jul-Aug; 16(4):576-81; discussion 581-2.
        View in: PubMed
      123. Fantl WJ, Escobedo JA, Martin GA, Turck CW, del Rosario M, McCormick F, Williams LT. Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways. Cell. 1992 May 1; 69(3):413-23.
        View in: PubMed
      124. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. Nature. 1991 Jan 10; 349(6305):117-27.
        View in: PubMed
      125. Landis CA, Harsh G, Lyons J, Davis RL, McCormick F, Bourne HR. Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein. J Clin Endocrinol Metab. 1990 Dec; 71(6):1416-20.
        View in: PubMed
      126. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: a conserved switch for diverse cell functions. Nature. 1990 Nov 8; 348(6297):125-32.
        View in: PubMed
      127. Kaplan DR, Morrison DK, Wong G, McCormick F, Williams LT. PDGF beta-receptor stimulates tyrosine phosphorylation of GAP and association of GAP with a signaling complex. Cell. 1990 Apr 6; 61(1):125-33.
        View in: PubMed
      Frank's Networks
      Click the "See All" links for more information and interactive visualizations!
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Same Department
      Back to TOP